India Iressa Direct Mail Purchasing India Iressa Sales Purchasing Center New Iressa Purchasing

r , / r br , Purchasing hotline Indian anti-cancer drugs are Indian generic drugs. Indian generic drugs are in an awkward position. Some do not have patents and some enter the Chinese market through underground channels. The low prices bring hope to the poor people and also bring hope to the poor. Pharmaceutical giants have caused huge profit losses. What should we think about Indian generic drugs? Generic drugs are not equivalent to fake drugs. Drug patents may kill the poor

r , / r br . Generic drugs are not fake drugs in terms of efficacy. The U.S. Food and Drug Administration approves generic drugs Production

r , / r br , There are two types of counterfeit drugs in general, one is counterfeit drugs at the therapeutic level and the other is counterfeit drugs at the legal level. In this case disclosed by the Legal Daily, Indian generic drugs were classified as the second category. According to the provisions of my country's "Drug Administration Law", for drugs sold in the Chinese market, domestic drugs must have a national drug approval number, and imported drugs must have a drug import registration certificate number. The anti-cancer drugs purchased by the criminal suspects were all regarded as fake because they did not have import registration certificate numbers in China.

r , / r br , This is not the first time such a case has occurred in China. In March 2019, He, an employee of a Shenzhen company stationed in India, began selling Indian anti-cancer drugs through the Internet. He first purchased anti-cancer drugs such as Iressa, Gleeveterol, and Calibrate from India, and then brought them to Shenzhen by mailing them through customs. In March 2018, He and other criminal suspects were captured by the public security organs.

r , / r br , There are two kinds of Indian medicines flowing into China, one is Indian generic medicine, and the other is fake Indian generic medicine. For authentic Indian generic drugs, they are regular drugs that are almost the same as patented drugs in terms of dose, safety, efficacy, quality, action, and indications, but are not bound by patents. Since there is no need to pay patent fees, the average price of generic drugs is only that of patented drugs, and the price difference for some varieties is even more than three times. India has always been known as the pharmacy of the world. The generic drug industry is very developed. Generally speaking, once expensive drugs in Western countries are launched, Indian pharmaceutical companies can copy similar products under the protection of their own patent laws.

r , / r br , The contradiction is that if there are no innovative drugs, where can we get generic drugs?

r , / r br , The lawsuits between pharmaceutical giants and generic drug companies continue, and the Indian government is determined to preserve its own generic drugs

r , / r br , According to the Associated Press, India’s Supreme Court recently rejected Swiss pharmaceutical giant Novartis’ request for patent protection for its improved new anti-cancer drug Gleevec. It is believed that India’s local generic cancer drugs can continue to be sold. The lawsuit is hailed as a battle between human rights and intellectual property rights in India.

r , / r br , India’s new anti-cancer drug Gleevec is imitated

r , / r br , According to According to the introduction, this drug is mainly used to treat chronic myelogenous leukemia and malignant gastrointestinal stromal tumors. It is an important anti-cancer drug at this stage. It has been widely used around the world and has been patented in several countries. However, Gleevec was not patented in India. According to India’s patent law, which was revised just this year, India only supports new drugs developed after this year, and does not support applications for patents on mixtures of existing drugs or derivative drugs. The reason why Gleevec was rejected was that an upgraded version of the new drug already existed in 2008 and was not considered an innovative drug. India, on the other hand, is also producing its own version of Gleevec. This generic drug is not much different in effect from Novartis' Gleevec. A month of treatment with Novartis Gleevec costs up to US$1, while Indian generics only cost less.

r , / r br , Switzerland’s Novartis is not the first Western pharmaceutical giant to try to challenge Indian patent laws. In March 2019, the Indian Patent Inspectorate issued a compulsory license, ordering the German pharmaceutical company Bayer to license a local pharmaceutical company to produce a kidney cancer drug r. Subsequently, Bayer filed a complaint with the Intellectual Property Appellate Board B of the Indian government in Chennai, requesting to overturn the compulsory license, but was rejected.

r , / r br , In order to defend its own generic drug industry, India also competes with Western pharmaceutical giants in the form of laws. Last month, India issued its first compulsory license for a patented drug, allowing local pharmaceutical companies to produce generic versions of Br's anti-liver and kidney cancer drug Nexavar. Indian patent office administrators determined that the drug was not being sold at a reasonable price to Indian patients. Since pharmaceutical patents usually only have a protection period of 10 years, after the patent expires, they will be imitated in large numbers, causing prices to plummet. In order to circumvent the patent protection period, some pharmaceutical companies extend the patent period through evergreen methods, that is, slightly adjusting the drug to apply for a new patent protection period in order to obtain high returns. Critics believe that evergreen will prevent generic drug manufacturers from making copies of patented drugs, making some well-known brand drugs unaffordable to patients.

r , / r br , The Secretary-General of the Indian Ministry of Medicine has publicly stated that in order to ensure that more poor people can afford originally expensive medicines, the government plans to expand medicine prices The control aspect includes bringing the first generic drugs of patented drugs into the scope of price control. If implemented, European and American pharmaceutical giants will face more severe challenges.

r , / r br , Generic drugs impact the interests of pharmaceutical giants. If interests are damaged, the development of new drugs will be hindered

r , / r br In the past, it was generally believed that the average cost of developing a new drug was about US$100 million. However, a recent data shows that the cost of developing a new drug is much more than this. Global pharmaceutical companies such as AstraZeneca spent about 100 million US dollars on research and development from 2010 to 2015, and only approved one new drug during this period. On average, Each new drug costs up to $100 million. The cost of each new drug listed in the table below includes many failed R&D projects. If only one successfully launched new drug is calculated, the R&D cost will be lower than this figure.



r , / r br , the largest generic drug manufacturer in India One of the companies, Cipla, said it would significantly cut the price of generic anti-cancer drugs. The company said it will cut the monthly supply price of a generic version of Bayer's Br's kidney and liver cancer drug R from rupee$$ to rupee$$. The monthly supply of Bayer's R-patented drug costs up to 10,000 rupees US$.